← SGLT2 inhibitors × cardiovascular events

TrialStroke2019

Canagliflozin and Stroke in Type 2 Diabetes Mellitus.

Zien Zhou et al.PubMed ↗Full text ↗Publisher ↗

A later paper about NCT01032629. The trial’s primary report, PMID 28605608, speaks for it on the map; the numbers here are shown and do not vote.

What the trial testedas reported · 312 people · 2019

Range includes no effect

No clear effect on cardiovascular events

Doesn’t vote: a later paper about the trial

−13%−31% to +9%

Bigger than 2 in 10 for cardiovascular events

As reported

HR 0.87, 95% CI 0.69–1.09

One number in the abstract

the abstract, start to end

… among placebo (hazard ratio, 0.87; 95% CI, 0.69-1.09).

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.870.69–1.09
SGLT2 inhibitorsCardiovascular events
1 / 3

33 papers cite it

2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

Full record →Abstract, authors, funding and every citing paper · PMID 30591006